{"disease":{"id":"idiopathic-myelofibrosis","name":"idiopathic myelofibrosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT01433445","title":"Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00433862","title":"Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}